Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1’s role in neuroprotection: a systematic review
Damla Erbil, Candan Yasemin Eren, Çağrı Demirel, et al.
Brain Injury (2019) Vol. 33, Iss. 6, pp. 734-819
Closed Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
Ruth Brauer, Li Wei, Tiantian Ma, et al.
Brain (2020) Vol. 143, Iss. 10, pp. 3067-3076
Open Access | Times Cited: 170
The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
James Mitchell, Hannah Lyons, Jessica Walker, et al.
Brain (2023) Vol. 146, Iss. 5, pp. 1821-1830
Open Access | Times Cited: 75
GLP-1a: Going beyond Traditional Use
Lucas Fornari Laurindo, Sandra Maria Barbalho, Élen Landgraf Guiguer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 739-739
Open Access | Times Cited: 71
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 21
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Leszek Szablewski
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 542-542
Open Access | Times Cited: 3
Arrestin‐independent internalization of the GLP‐1 receptor is facilitated by a GRK, clathrin, and caveolae‐dependent mechanism
Ee Von Moo, Thor C. Møller, Flemming Brandt Sørensen, et al.
FEBS Journal (2025)
Open Access | Times Cited: 2
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Christian Hölscher
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 695-714
Open Access | Times Cited: 98
Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
Candan Yasemin Eren, Arya Yigit, Ramazan Efe Dogruoz, et al.
Frontiers in Behavioral Neuroscience (2021) Vol. 14
Open Access | Times Cited: 74
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Paul Edison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 217-229
Open Access | Times Cited: 70
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Haiyang Du, Xiaoyu Meng, Yao Yu, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 53
The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Dihe Cheng, Shuo Yang, Xue Zhao, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 665-684
Open Access | Times Cited: 44
Diabetes and cognitive function: An evidence-based current perspective
Meghna Julian Sebastian, Shahanas K A Khan, Joseph M Pappachan, et al.
World Journal of Diabetes (2023) Vol. 14, Iss. 2, pp. 92-109
Open Access | Times Cited: 39
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
Daniel Cooper, Ranuk Ramachandra, Felicia Ceban, et al.
Journal of Psychiatric Research (2023) Vol. 164, pp. 80-89
Closed Access | Times Cited: 33
Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
Rodrigo B. Mansur, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
CNS Spectrums (2025), pp. 1-6
Closed Access | Times Cited: 1
Investigating the impact of intestinal glucagon-like peptide-1 on hypoglycemia in type 1 diabetes
Mahmoud Nassar, Angad Singh Gill, Erlin Marte
World Journal of Diabetes (2025) Vol. 16, Iss. 3
Open Access | Times Cited: 1
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access | Times Cited: 1
Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology
Melania Gaggini, Laura Sabatino, Adrian Florentin Suman, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 387-387
Open Access | Times Cited: 1
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: A narrative review
Miquel Bioque, Alexandre González-Rodríguez, Clemente García‐Rizo, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 105, pp. 110130-110130
Closed Access | Times Cited: 52
Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke
Shereen Nizari, Marina Basalay, Philippa Chapman, et al.
Basic Research in Cardiology (2021) Vol. 116, Iss. 1
Open Access | Times Cited: 52
Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins’ Mimicry of Human Protein Interactions
Hale Yapıcı Eser, Yunus Emre Köroğlu, Özgür Öztop Çakmak, et al.
Frontiers in Human Neuroscience (2021) Vol. 15
Open Access | Times Cited: 50
Impaired brain insulin signalling in Parkinson's disease
Fares Bassil, Anna Delamarre, Marie‐Hélène Canron, et al.
Neuropathology and Applied Neurobiology (2021) Vol. 48, Iss. 1
Closed Access | Times Cited: 49
Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research
Xiaoyan Yang, Qiang Qiang, Nan Li, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 37
Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
Xavier Morató, Vanesa Pytel, Sara Jofresa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9305-9305
Open Access | Times Cited: 34
Association between Parkinson’s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment
Haiyang Yu, Tong Sun, He Xin, et al.
Aging and Disease (2022) Vol. 13, Iss. 6, pp. 1591-1591
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top